전립선비대증을 동반한 발기부전 환자에서 Mirodenafil 50mg 매일 복용요법과 100mg 필요 시 복용요법의 유효성 비교: 다기관, 무작위 대조 연구
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조중훈 | - |
dc.contributor.author | 서준상 | - |
dc.contributor.author | 김규식 | - |
dc.contributor.author | 김태효 | - |
dc.contributor.author | 노준화 | - |
dc.contributor.author | 배재현 | - |
dc.contributor.author | 오철영 | - |
dc.contributor.author | 이승환 | - |
dc.contributor.author | 조성용 | - |
dc.contributor.author | 최재덕 | - |
dc.contributor.author | 한준현 | - |
dc.contributor.author | 이승욱 | - |
dc.date.accessioned | 2022-07-15T19:42:46Z | - |
dc.date.available | 2022-07-15T19:42:46Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2015-12 | - |
dc.identifier.issn | 1598-8341 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/155610 | - |
dc.description.abstract | Purpose: To Compare the improvement of erectile dysfunction(ED) and lower urinary tract symptoms(LUTS) as well as the efficacy of mirodenalfil 50mg once daily and 100mg on-demand in patients with benign prostatic hyperplasia(BPH) and erectile dysfunction(ED). Materials and Methods: Prospective study was done with 220 patients who had BPH and ED from June 2013 to October 2014. Out of 220 individuals, 260 met inclusion criteria and 204 finished the research. Patients were divided into two groups. Group 1 had mirodenafil 50mg once daily and Group 2 had mirodenafil 100mg on-demand. The five-item version of the International Index of Erectile Function(IIEF-5), International Prostate Symptom Score(IPSS), Qmax, and residual urine volume(PVR) were assessed immediately before initiation of treatment(V1) and after four(V2) and twelve weeks of treatment(V3). Results: No difference of IIEF-5, IPSS, Qmax, and PVR between two groups in V1. At V3, both groups had improvements of IPSS and group 1 had better improvements(-5.1±4.4 vs. -3.1±3.9 p<0.001). And Group 1 had larger improvements than Group 2 in Qmax significantly. No difference in PVR in both groups comparing V1 vs. V2 and V1 vs V3. Group 1 had better improved IIEF-5 than Group 2(V1 vs. V3 : 4.8±5.8 vs. 4.4±5.1; p=0.032). There was no drop out patients due to cardiovascular problems. Conclusions: Once daily mirodenafil 50mg was more efficacious in treating both ED and LUTS than on-demand dosing mirodenafil 100mg without any complication of cardiovascular problems. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한비뇨기종양학회 | - |
dc.title | 전립선비대증을 동반한 발기부전 환자에서 Mirodenafil 50mg 매일 복용요법과 100mg 필요 시 복용요법의 유효성 비교: 다기관, 무작위 대조 연구 | - |
dc.title.alternative | Comparison of Erectile Dysfunction Treatment Efficacy of Mirodenalfil 50mg Once Daily and 100mg On-Demand in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction: Multicenter, Randomized | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 김규식 | - |
dc.contributor.affiliatedAuthor | 이승욱 | - |
dc.identifier.bibliographicCitation | 대한비뇨기종양학술지, v.13, no.3, pp.115 - 121 | - |
dc.relation.isPartOf | 대한비뇨기종양학술지 | - |
dc.citation.title | 대한비뇨기종양학술지 | - |
dc.citation.volume | 13 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 115 | - |
dc.citation.endPage | 121 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002079835 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | other | - |
dc.subject.keywordAuthor | Mirodenafil | - |
dc.subject.keywordAuthor | Lower urinary tract symptoms | - |
dc.subject.keywordAuthor | Erectile dysfunction | - |
dc.subject.keywordAuthor | Benign prostatic hyperplasia | - |
dc.identifier.url | http://www.dbpia.co.kr/journal/articleDetail?nodeId=NODE06599333 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.